



Barbara Davis Center for Diabetes  
UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

# 3rd Childhood Diabetes Prevention Symposium

## General Population Screening for T1D: CURRENT ISSUES in time of COVID-19

NOVEMBER 13, 2020 / A VIRTUAL (ZOOM) EVENT

### THE OBJECTIVES OF THIS SYMPOSIUM ARE TO:

1 Summarize current screening efforts worldwide

2 Discuss lessons learned from adjustments made for COVID-19 pandemic

3 Prioritize goals for the next 3 years

- Type 1 diabetes (T1D) affects 1.4 million people in the U.S.
- Clinical diagnosis is preceded by months or years of pre-symptomatic autoimmunity damaging insulin-producing cells in the pancreas. It can be detected through inexpensive screening for islet autoantibodies.
- The JDRF, the ADA, and the Endocrine Society have recognized that T1D should be diagnosed when a child develops multiple islet autoantibodies (stage 1), irreversibly progressing to dysglycemia (stage 2), and clinical diabetes (stage 3 T1D).
- Early detection of stage 1 T1D through screening is important because parents and providers often overlook symptoms of diabetes.
- As the result, 50% of children newly diagnosed with T1D in the U.S. present with life-threatening diabetic ketoacidosis (DKA). They are at high risk of brain swelling, permanent memory deficits, and poor long-term diabetes control due to additional loss of insulin-producing cells during DKA.
- Screening for autoantibodies can reduce the risk of DKA to less than 5% and is cost-effective with a lifetime horizon.
- In addition, children identified through the screening as high-risk can participate in clinical trials to delay or prevent clinical diabetes.



The Barbara Davis Center for Diabetes (BDC) specializes in Type 1 Diabetes (T1D) research and care for children and adults. It is one of the largest diabetes institutes in the world. The Center is part of the University of Colorado School of Medicine and has its dedicated building on the Anschutz Medical Campus in Aurora, Colorado.

The Center was funded by Marvin and Barbara Davis, in 1978, and is generously supported by the Children's Diabetes Foundation (CDF).

Clinicians, clinical researchers, and basic biomedical scientists work at the BDC to find the most effective treatment, prevention, and cure for T1D. The Center provides state-of-the-art diabetes care to 4,200 children and 2,800 adults with diabetes from the Rocky Mountain Region as well as receiving national and international referrals. We also provide inpatient care to patients who are seen at the Children's Hospital Colorado with any type of diabetes.

[www.barbaradaviscenter.org](http://www.barbaradaviscenter.org)

# AGENDA

## General Population Screening for T1D: CURRENT ISSUES in time of COVID-19

NOVEMBER 13, 2020 / A VIRTUAL (ZOOM) EVENT

\* All times EST

- |          |   |          |  |
|----------|---|----------|--|
| 10:00am  | <b>WELCOME &amp; INTRODUCTION</b><br><b>Marian Rewers MD, PhD</b><br><i>Barbara Davis Center for Diabetes</i>       | 11:00am  | <b>OPTIMAL AGE TO SCREEN/RESCREEN</b><br><b>William Hagopian MD, PhD</b><br><i>Pacific Northwest Diabetes Research Institute</i> |
| 10:05am  | <b>JDRF PERSPECTIVE</b><br><b>Frank Martin PhD</b><br><i>JDRF Research Cure/Prevention</i>                          | 11:10am  | <b>T1D1 SCREENING TOOLBOX</b><br><b>Mohamed Ghalwash PhD</b><br><i>Center for Computational Health, IBM Research</i>             |
| 10:10am  | <b>HELMSLEY TRUST PERSPECTIVE</b><br><b>Anne Koralova PhD</b><br><i>Helmsley Charitable Trust T1D Program</i>       | 11:15am  | <b>THE SANFORD PROJECT</b><br><b>Kurt Griffin MD, PhD &amp; Nancy Konopasek BSRT</b><br><i>Sanford Health</i>                    |
| 10:15am  | <b>PUBLIC PRIVATE PARTNERSHIP INITIATIVE</b><br><b>Jessica Dunne PhD</b><br><i>Janssen Research and Development</i> | 11:25am  | <b>AUSTRALIAN T1D SCREENING PROJECT</b><br><b>Kirstine Bell PhD</b><br><i>Sydney University</i>                                  |
| 10:30 am | <b>UPDATE FROM FR1DOLIN</b><br><b>Olga Kordonouri MD, PhD</b><br><i>Hannover Children's Hospital</i>                | 11:30am  | <b>ISRAELI T1D SCREENING PROJECT</b><br><b>Tal Oron MD</b><br><i>Schneider Children's Medical Center of Israel</i>               |
| 10:40 am | <b>UPDATE FROM PRIMED</b><br><b>Stephen Rich PhD</b><br><i>Center for Public Health Genomics, UVA</i>               | 11:35 am | <b>PUBLIC HEALTH SARS-COV-2 ANTIBODY SCREENING</b><br><b>Markus Hippich MD</b><br><i>Helmholz Institute, Munich</i>              |
| 10:50 am | <b>UPDATE FROM ASK</b><br><b>Marian Rewers MD, PhD</b><br><i>Barbara Davis Center for Diabetes</i>                  | 11:40 am | <b>Q &amp; A</b>   |
|          |   | 12:00 Pm | <b>ADJOURN</b>   |

